Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-intensity inpatient MDMA-assisted psychotherapy for treatment-refractory PTSD
NL-OMON59220Phase 2Recruiting
- Sponsor
- ARQ National Psychotrauma Centre
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by ARQ National Psychotrauma Centre. Primary endpoint: Change in CAPS-5-R Total Severity Score. Started May 2025; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON59220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59220.